Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
ZuvaChem was a private U.S. industrial biotechnology company focused on using metabolically engineered photosynthetic microorganisms to convert carbon dioxide into hydrocarbon chemicals. Its lead work centered on producing polymer-grade isoprene, a key precursor for renewable rubber and tire applications, and related carbonaceous chemicals. The company appears to have operated as an early-stage platform business built around photobiosynthetic reactor systems, engineered microbes, and associated intellectual property. In May 2015, ZuvaChem merged with BioSyntha Technology to form ZuvaSyntha, so ZuvaChem no longer appears to operate as an independent active company. The business was not a therapeutics or healthcare company, but rather a renewable/industrial chemicals venture adjacent to synthetic biology and biomanufacturing.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on ZuvaChem.